| Factor Information | |
|---|---|
| Data ID | 1840 |
| Factor | Systolic pulmonary artery pressure |
| Description | Systolic pulmonary artery pressure showed no significant changes at 2 (93.6±17.2 mmHg) and 4 months (85.7±25.5 mmHg) of bosentan treatment compared to that before the medication (97.8±14.9 mmHg) (P= 0.096), but decreased significantly after a 6- month therapy (80.9 ± 25.0 mmHg, P=0.029). |
| Biomarker | NA |
| Classification | E9 (physiological factor - hemodynamic parameter) |
| Association | |
|---|---|
| Application | Treatment |
| Objective | Systolic PA pressure decreased significantly after a 6-month therapy |
| p Value | 0.029 |
| Conclusion | Oral bosentan can effectively relieve the symptoms, decrease PA hypertension, and improve exercise tolerance and cardiac function classification in patients with PA hypertension associated with congenital heart disease with good safety and mild side effects. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 554 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | VSD/VSD, PDA/AS/PDA/VSD, PDA/DORV, VSD/AVSD/ES |
| Reference | |
|---|---|
| PMID | 25537917 |
| Year | 2015 |
| Title | Efficacy of oral bosentan for treatment of congenital heart disease-associated pulmonary arterial hypertension |
| Sample | ||
|---|---|---|
| Population | All | |
| Source | N/A | |
| Region | Beijing, China | |
| Method | Liver and kidney function, again measured 6MWD, color echocardiography of the heart, and evaluated cardiac function grading, and measured oxygen saturation | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | 6 months of bosentan treatment(Treatment) | before the medication(Control) |
| Number | 24 | N/A |
| Age | 23.8±17.6 (5~57) years | 23.8±17.6 (5~57) years |
| Gender (Male: Female) | 8:16 | N/A |
| Marker Level | 80.9 ± 25.0 mmHg | 97.8±14.9 mmHg |
